Actively Recruiting
Decipher Lethal Prostate Cancer Biology - Urine Metabolomics
Led by National Taiwan University Hospital · Updated on 2026-01-20
2000
Participants Needed
1
Research Sites
521 weeks
Total Duration
On this page
Sponsors
N
National Taiwan University Hospital
Lead Sponsor
T
Taipei Medical University Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Through a better understanding of the biology of significant (lethal) prostate cancer, we hope to develop new markers/targets from urine metabolomics for more effective screening and prevention of significant prostate cancer. In the meantime, with these new markers we may substantially reduce overtreatment of insignificant PC.
CONDITIONS
Official Title
Decipher Lethal Prostate Cancer Biology - Urine Metabolomics
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men aged 30 to 100 years
- Men planning to undergo prostate biopsy or who completed biopsy within 6 weeks
- Prostate cancer patients undergoing rebiopsy with normal testosterone levels (>1.5 ng/ml)
- Ability to understand study procedures and consent to urine donation and clinical data use
You will not qualify if you...
- Having other active cancers except those disease-free for 3 or more years after curative treatment
- Severe organ impairment affecting metabolism, such as high creatinine (>3.0), high HbA1c (>9.0%), symptomatic heart failure, or other metabolic diseases
- Receiving systemic therapy (chemotherapy, hormone therapy, immunotherapy, targeted therapy) within 3 months
- Receiving pelvic radiotherapy within 3 months
- Significant infection or inflammation within 8 weeks of biopsy
- Having pyuria (>5 WBC/HPF) within 4 weeks of biopsy
- Using prednisolone equivalent >10 mg daily for 14 days or more
- Having taken prednisolone within 4 weeks of biopsy
- Life expectancy less than 12 months
- Using MCS or supplements with high lycopene (>2 mg/day) within the last 60 days
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Urology, National Taiwan University Hospital
Taipei, Taiwan, 100
Actively Recruiting
Research Team
C
Chung-Hsin Chen, MD PhD
CONTACT
Y
Yeong-Shiau Pu, MD PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here